The US Food and Drug Administration (FDA) has approved Eton Pharmaceuticals’ liquid therapy Desmoda, an oral solution formulation of desmopressin indicated for the treatment of central diabetes insipidus, also referred to as arginine vasopressin deficiency (AVP-D).

Central diabetes insipidus is a rare endocrine disorder characterised by deficiency of antidiuretic hormone, resulting in excessive urination and increased thirst. The approval introduces a ready-to-use liquid formulation designed to enable precise dose titration compared with existing tablet-based desmopressin therapies.

Desmoda is supplied as a 0.05 mg/mL oral solution, eliminating the need for tablet splitting or manipulation and supporting accurate dosing adjustments based on patient requirements. Dose precision is considered critical in the management of AVP-D, where variations in dosing may impact fluid balance and sodium levels.

The therapy is approved for use in both adult and pediatric patient populations. Eton Pharmaceuticals expects commercial availability through specialty distribution channels, supporting treatment access for patients requiring long-term hormone replacement therapy.

The approval expands Eton Pharma’s portfolio within the rare disease and specialty pharmaceutical segment, strengthening its presence in endocrine therapies.

Desmoda carries safety warnings associated with hyponatremia, fluid retention and hypersensitivity reactions, requiring appropriate clinical monitoring during treatment.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!